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Objective: In patients with trapeziometacarpal arthrosis, we tested the hypothesis that there is no dif-
ference in arm-speciﬁc disability 5e15 weeks after prescription of a pre-fabricated neoprene or a
custom-made thermoplast hand-based thumb spica splint with the metacarpophalangeal joint included
and the ﬁrst interphalangeal joint free.
Method: One hundred nineteen patients with a diagnosis of trapeziometacarpal arthrosis were pro-
spectively randomized to wear either a neoprene or a thermoplast hand-based thumb spica splint. At
enrollment, patients completed a set of validated questionnaires. An average of 9 weeks later, patients
returned for a second visit. Bivariable analyses assessed factors associated with disability, pain and
satisfaction. Analysis was by intention-to-treat.
Results: Sixty-two patients (32 with a neoprene and 30 with a thermoplast splint) completed the study,
51 patients (43%) did not return for the second visit, and six did not complete the protocol for other
reasons. Non-completers were signiﬁcantly younger than completers (P < 0.00044). On average com-
pleters rated the neoprene splint as more comfortable (P ¼ 0.048), but there were no detectable dif-
ferences in Disabilities of the Arm, Shoulder and Hand (DASH), change in DASH, pain, satisfaction, pinch
or grip strength between the two splint types in our sample.
Conclusion: When compared to custom-made thermoplast splints, pre-fabricated neoprene hand-based
thumb spica splints are, on average, more comfortable, less expensive, and as effective in treating tra-
peziometacarpal arthrosis.
This trial was registered at Clinicaltrials.gov (NCT00438763).
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
A hand-based thumb spica splint with the interphalangeal (IP)
joint free is a speciﬁc nonoperative palliative treatment for tra-
peziometacarpal (TMC) arthrosis. The goals of splint wear are
improved comfort and function1e4. The data regarding speciﬁc
splint materials are limited, but suggest that shorter more ﬂexible
splints are preferred by patients and equally effective4,5.
This randomized prospective clinical trial of patients with a
diagnosis of TMC arthrosis tested the null hypothesis that there is
no difference in arm-speciﬁc disability 5e15 weeks after
prescription of a pre-fabricated neoprene hand-based thumbo: S.J.E. Becker, Orthopaedic
eneral Hospital, Yawkey Cen-
A. Tel: 1-617-726-1569; Fax:
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).
s Research Society International. Pspica splint with the metacarpophalangeal (MP) included and the
IP joint free or a similar custom-made thumb spica splint from
thermoplast. Secondary study questions addressed the null hy-
potheses that there are no statistically signiﬁcant differences be-
tween a neoprene and thermoplast splint regarding improvement
of disability, pain at follow-up and satisfaction with the splint; that
arm-speciﬁc disability does not correlate with higher scores on
instruments assessing psychological factors; and that no factors
associate with higher arm-speciﬁc disability, pain and satisfaction.
We also examined the percentage of patients that had surgery
within the study period.Method
The Human Research Committee at our institution in the United
States approved this prospective, single center, unblinded, equally
randomized [1:1] controlled parallel-group clinical trial comparing
hand-based thumb spica splints of pre-fabricated neoprene with
custom-made thermoplast for patients with TMC arthrosis.ublished by Elsevier Ltd. All rights reserved.
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adult patients that requested a splint for TMC arthrosis were
enrolled from the outpatient ofﬁce of two hand surgeons at one
tertiary care hospital. Patients were considered eligible for this trial
if they were 18 years or older and clinically diagnosed with TMC
arthrosis by the hand surgeon. Additional radiological assessment
was not considered necessary for the diagnosis. Patients were not
eligible if they had a history of surgically treated TMC arthrosis.
Randomization
The allocation was concealed from the independent research
assistant until informed consent was obtained. After informed
consent was obtained, patients were randomly assigned to either a
neoprene or a thermoplast splint, according to a computer gener-
ated sequence of random numbers (Windows Excel; Microsoft,
Redmond, WA). Splint assignment was not blinded to any of the
involved parties.
Intervention
According to the randomization, a trained occupational thera-
pist provided either a pre-fabricated neoprene Comfort Cool
Thumb CMC Restriction Splint (North Coast Medical, Gilroy, CA) or a
customized 3.2 mm thick thermoplast hand-based thumb spica
splint with theMP included, and the IP joint and wrist free. Patients
were told to wear the splint as needed for pain relief with daily
activities and even at night if it helped them sleep. This was a
pragmatic clinical trial, and consistent with usual practice, patients
were not prohibited from using other treatments including other
splints. Patients were allowed to have their splint adjusted.
Evaluation
An independent research assistant not involved in patient care
evaluated patients at both time points.
At time of enrollment, each patient completed the Disabilities of
the Arm, Shoulder and Hand (DASH) questionnaire6, the Pain
Anxiety Symptoms Scale (PASS)7, the Pain Catastrophizing Scale
(PCS)8, the Center for Epidemiological Studies e Depression scale
(CES-D)9,10 and the Whiteley Index11. In addition, pinch and grip
strength were recorded, and painwas measured on an ordinal scale
from 0 (no pain) to 10 (worst pain you ever had). Pain improvement
was calculated by deducting the follow-up pain score from the
initial pain score.
Patients were asked to return 5e15 weeks later to complete the
DASH questionnaire, ordinal scales for pain and satisfaction with
the splint, and grip and pinch strength. The six 11-point ordinal
satisfaction scales asked for (1) satisfaction with the splint, (2)
how the splint helped in terms of pain relief, (3) how the splint
helped in keeping active, doing daily living activities, (4) if the
splint improved quality of life, (5) how comfortable wearing the
splint was, and (6) how easy it was to follow the hand therapist
instructions regarding splint use. A higher score indicates greater
satisfaction or help. If patients did not return within the approved
window between 5 and 15 weeks after enrollment, an
independent research assistant tried to contact them by phone, a
maximum of three times, to schedule a research appointment.
Both grip and pinch strength were measured as the average of
three attempts. Grip strength was measured using the Jamar
dynamometer (Asimov Engineering, Los Angeles, California) with
the hand grip placed at the second or third station depending on
the hand size. During the grip strength testing, the arm was at the
side, the elbow at 90 ﬂexion, and the forearm and wrist in neutral
position. Key pinch strength was recorded using the B&L pinchgauge (B&L Engineering, Santa Ana, California) with the thumb pad
on the pinch gauge and the lateral aspect of the middle phalanx of
the index ﬁnger underneath. Both grip and pinch strength of the
affected hand were compared with the opposite or least involved
(in case of bilateral involvement) side. Whenever grip and pinch
strength are mentioned, these refer to the percentage of strength
calculation (involved/noninvolved hand).
Outcome measures
This study was designed with a single primary study question
with a single primary endpoint. All other analyses should be
considered secondary and hypothesis-generating. The primary
endpoint was the DASH score at 5e15 weeks follow-up. Secondary
endpoints were DASH score at enrollment, improvement in DASH
score, pain intensity at both time points, improvement in pain in-
tensity, grip and pinch strength at both time points, and satisfaction
at follow-up. The remaining variables were all considered to be
explanatory variables. Study participation was considered com-
plete if the DASH questionnaire was completed at both time points.
Sample size analysis
An a-priori sample size analysis using a two-tailed Student’s
t test estimated the need to evaluate 60 participants to detect a
clinically relevant difference of 10 points in follow-up DASH scores
between the two prospective cohorts at 90% power, and a signiﬁ-
cance level of 0.05. When we were close to our target enrollment
number of 60 subjects, approximately half of the study population
had not returned for the 5e15 weeks evaluation. Therefore, the
target was raised to 120 patients.
Statistical analysis
Analysis was by intention-to-treat, meaning that patients were
analyzed based on the type of splint assignment irrespective of
what splint they actually received from the occupational therapist.
In other words, this was a pragmatic trial12,13 comparing the
effectiveness (the effect of prescribing a certain type of splint in
actual practice where patients do not follow prescriptions pre-
cisely) rather than the efﬁcacy (how the splints work under ideal
conditions) of each splint.
Continuous variables are reported with means, standard de-
viations, and ranges. The data was not normally distributed ac-
cording to the KolmogoroveSmirnov test and therefore non-
parametric tests were done to determine the relationship be-
tween two variables. The ManneWhitney U test was conducted to
evaluate the difference in mean between two groups. The Kruskale
Wallis test was used to assess the difference in mean betweenmore
than two groups. The relationship between categorical variables
was evaluated with use of the Pearson Chi-Square test. Spearman
correlations were used to assess the relationship between contin-
uous variables. The difference between items measured at both
time points (e.g., DASH questionnaire) were evaluated with the
Wilcoxon Signed-Rank test.
Any DASH questionnaires with 4 and 5 missing items (5 at
enrollment and 1 at follow-up) were analyzed. In case of missing
items on a questionnaire, the scorewas scaled based on the number
of items completed by the patient, taking into account any reverse
scored items. The adjusted total scores were rounded to the nearest
integer. This methodwas used for the following questionnaires (not
more than 21% of itemsweremissing per patient): PASS, PCS, CES-D
and Whiteley Index. Only for data of the patients that completed
study participation, a few missing data points were imputed with
themean cohort score for the speciﬁc questionnaire or scale. One or
S.J.E. Becker et al. / Osteoarthritis and Cartilage 21 (2013) 668e675670more missing values of patients that did not complete the study
were excluded from an analysis if it required the missing data.
The SPSS software program, version 15.0, was used for all sta-




An overview of the participant ﬂow is shown in Fig. 1. Three pa-
tients completed the study at 27, 29 and 65 weeks after enrollment
respectively because they missed their original scheduledAssessed for elig
Analyzed: n = 32
Excluded from analysis: n = 28
Lost to follow-up: n = 27
Hand tumor excised from arthritic hand during 
study period: n = 1
5-15 weeks evaluation: n = 33
Additional interventions: n = 2
Changed to thermoplast and again back to 
neoprene: n = 1
Got additional night splints for carpal tunnel
syndrome: n = 1
Neoprene: n = 61
Received neoprene: n = 53
Received thermoplast: n = 3
Received forearm-based thumb spica: n = 1
Received both neoprene and thermoplast: n =2
Participation terminated: n = 1
Decided not to wait to have a splint made: n = 1
Randomized
Fig. 1. Diagram detailing paappointment and returned late. Sixty-two patients (52%) completed
the study an average of 9  9 weeks (range, 4e65 weeks) after
enrollment: 32 patients (54%) in the neoprene cohort and 30
patients (56%) in the thermoplast cohort. These 62 patients that
completed the study were, on average, about 6 years older than 51
patients that did not return (P < 0.00044) (Table I).
Numbers analyzed
All followingmentionedmissing data points were imputedwith
the mean cohort score for the speciﬁc questionnaire or scale. At
enrollment, the pain scale, CES-D questionnaire andWhiteley Index
were completed by 61 of 62 patients in total. Grip and pinchibility: n = 122
Not enrolled: n = 3
Declined to participate: n = 3
5-15 weeks evaluation: n = 32
Additional interventions: n = 2
Changed to neoprene: n = 2
Thermoplast: n = 58
Received thermoplast: n = 54
Received both neoprene and thermoplast: n = 1
Received long opponens: n = 1
Participation terminated: n = 2
Decided to terminate study before completing 
measurements:  n = 1
Decided not wanting to be randomized: n = 1
: n = 119
Analyzed: n = 30
Excluded from analysis: n = 26
Lost to follow-up: n = 24
Invalid DASH questionnaires at both time points: 
n = 2
tient ﬂow in the trial.
Table I
Completers vs non-completers





Mean SD Range Mean SD Range Correlation P value
Baseline
Age (years) 63.0 8.1 46e83 57.3 9.4 41e79 0.00044
Education (years) (n ¼ 112) 15.7 2.6 10e20 15.1 3.1 8e23 NS 0.13
DASH (n ¼ 112) 28.1 17.2 2.5e72.4 28.8 16.9 2.5e65.8 NS 0.74
Pain (n ¼ 112) 5.0 2.2 1e10 5.4 2.3 0e10 NS 0.28
PASS (n ¼ 110) 45.3 28.7 12e133 49.9 28.9 8e120 NS 0.17
PCS (n ¼ 112) 5.6 5.7 0e26 8.6 8.4 0e31 NS 0.10
CES-D (n ¼ 111) 8.9 9.3 0e47 11.0 10.1 0e40 NS 0.32
Whiteley Index (n ¼ 112) 24.1 8.5 14e50 25.3 8.4 16e46 NS 0.35
Grip strength (%) (n ¼ 110) 80.1 24.5 17.3e148.2 84.7 23.9 18.2e125.6 NS 0.14
Pinch strength (%) (n ¼ 110) 83.8 21.4 25.7e160.7 84.9 22.0 13.2e116.7 NS 0.30





Number % Number % Correlation P value
Baseline
Cohort NS 0.89
Neoprene splint 32 51.6 27 52.9
Thermoplast splint 30 48.4 24 47.1
Sex NS 0.72
Male 14 22.6 13 25.5
Female 48 77.4 38 74.5
Marital status (n ¼ 112) NS 0.56
Single 11 17.7 7 14.0
Married/living with partner 42 67.8 32 64.0
Separated/widowed 9 14.5 11 22.0
Affected thumb NS 0.94
Left thumb 24 38.7 20 39.2
Right thumb 26 41.9 20 39.2
Both thumbs 12 19.4 11 21.6
Dominant hand affected NS 0.90
Yes 37 59.7 31 60.8
No 25 40.3 20 39.2
n ¼ number; SD ¼ standard deviation; NS ¼ not signiﬁcant. The numbers in bold indicate signiﬁcant P values (P < 0.05).
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from the splint in terms pain of relief, help from the splint in
keeping active and doing daily activities, and improvement of
quality of life were rated by 61 patients. Satisfaction with the splint
and comfort of the splint were rated by 60 patients. The ease of
following the hand therapist instructions regarding splint use was
rated by 59 patients. Pain improvement could not be calculated for
two patients, and grip and pinch strength was measured in 61
patients because one patient could not return to the clinic but did
want to complete the study so instead the follow-up survey was
completed over the phone.
Baseline characteristics of cohorts
An overview of the two cohorts’ baseline characteristics is given
in Table II.
Follow-up comparison of cohorts
The only signiﬁcant difference between the two splints was
comfort (5.3 vs 6.8 points, P ¼ 0.048), in favor of patients that were
assigned to a neoprene splint (Table II).
Predictors of initial DASH score
In bivariable analysis, there was a signiﬁcant association be-
tween the initial DASH score and sex (r ¼ 0.26, P ¼ 0.042), the PCSscore (r ¼ 0.27, P ¼ 0.035) and the CES-D score (r ¼ 0.33,
P ¼ 0.0081) (Table III).
Predictors of follow-up DASH score
The average DASH score did not decrease signiﬁcantly from a
mean of 28  17 points (range, 2.5e72) at enrollment to a mean of
25  15 points (range, 3.3e63) at follow-up (P ¼ 0.21).
In bivariable analysis, the follow-up DASH score correlated
signiﬁcantly with the CES-D score (r ¼ 0.30, P ¼ 0.019) and the
Whiteley Index score (r ¼ 0.33, P ¼ 0.0098) (Table IV).
Predictors of follow-up pain rating
The average pain decreased signiﬁcantly fromameanof 5.0 2.2
points (range, 1e10) at enrollment to a mean of 4.2  2.1 points
(range, 0e9) at follow-up (P¼0.048). Pain improved0.9 2.6 points
on average (range, 4 points less to 7 points greater pain).
In bivariable analysis, there was a signiﬁcant correlation be-
tween follow-up pain rating and education (r ¼ 0.30, P ¼ 0.017),
the PCS score (r ¼ 0.30, P ¼ 0.018) and the CES-D score (r ¼ 0.30,
P ¼ 0.018) (Table V).
Predictors of satisfaction
Overall satisfaction with the splint, regardless of what type,
averaged 6.3  2.8 points (range, 0e10). Higher rated help from
Table II
Neoprene vs thermoplast group





Number % Number %
Baseline
Sex
Male 8 25.0 6 20.0
Female 24 75.0 24 80.0
Marital status
Single 6 18.8 5 16.7
Married/living with partner 20 62.4 22 73.3
Separated/widowed 6 18.8 3 10.0
Affected thumb
Left thumb 11 34.4 13 43.3
Right thumb 13 40.6 13 43.3
Both thumbs 8 25.0 4 13.4
Dominant hand affected
Yes 20 62.5 17 56.7
No 12 37.5 13 43.3





Mean SD Range Mean SD Range
Baseline
Age (years) 63.3 8.5 46e83 62.8 7.7 51e78
Education (years) 15.4 2.7 10e20 16.0 2.5 11e20
DASH 27.3 17.9 2.5e72 29.1 16.6 7.8e61
Pain 5.0 2.0 1e10 5.0 2.4 2e9
PASS 51.6 32.5 14e133 38.6 22.5 12e102
PCS 5.6 6.0 0e26 5.7 5.5 0e24
CES-D 8.8 8.6 0e33 9.0 10.1 0e47
Whiteley Index 25.5 9.8 14e50 22.6 6.7 16e43
Grip strength (%) 77.9 25.5 17e148 82.4 23.7 32e145
Pinch strength (%) 82.5 24.4 26e161 85.2 17.8 48e121





95% CI mean difference P value
Mean SD 95% CI Mean SD 95% CI
Follow-up
Follow-up time (weeks) 9.8 11.0 5.6e65 7.5 4.6 3.6e30 1.7 to 6.5 0.33
DASH 24.8 15.2 3.3e62 25.3 14.6 3.3e63 74 to 7.7 0.71
Improvement of DASH score 2.5 17.4 33 to 57 3.8 13.2 28 to 40 9.8 to 5.9 0.50
Pain 4.3 2.1 0e8 4.2 2.2 1e9 1.0 to 1.1 0.78
Improvement of pain 0.81 2.9 4 to 7 0.90 2.2 3 to 7 1.4 to 1.2 0.74
Splint satisfaction 6.7 3.0 0e10 5.9 2.6 2e10 0.58 to 2.2 0.19
Help in terms of pain relief 6.3 2.8 0e10 5.8 2.8 0e10 0.83 to 2.0 0.43
Help keeping active and doing daily activities 5.7 3.4 0e10 5.1 3.3 0e10 1.0 to 2.4 0.51
Improvement of quality of life 5.8 3.2 0e10 5.2 3.2 0e10 0.93 to 2.3 0.45
Comfort of splint 6.8 3.1 0e10 5.3 3.1 0e10 0.058 to 3.0 0.048
Ease of following hand therapist instructions regarding use 9.0 2.0 2e10 8.9 1.4 5e10 0.65 to 1.1 0.13
Grip strength (%) 85.0 23.2 42e161 92.0 30.4 50e217 21.3 to 5.8 0.52
Pinch strength (%) 91.9 19.6 41e133 89.5 19.3 49e127 7.6 to 12.2 0.90
The numbers in bold indicate signiﬁcant P value (P < 0.05).
S.J.E. Becker et al. / Osteoarthritis and Cartilage 21 (2013) 668e675672the splint in keeping active and doing daily activities was
signiﬁcantly associated with women (r ¼ 0.26, P ¼ 0.037). There
were small but signiﬁcant associations between satisfaction with
therapist instructions and fewer symptoms of depression
(r ¼ 0.27, P ¼ 0.035), less catastrophic thinking (r ¼ 0.29,
P ¼ 0.022), and less heightened illness concern (r ¼ 0.33,
P ¼ 0.0099) (Table VI).
Grip and pinch strength
Grip strength improved slightly, but signiﬁcantly from amean of
80  25% (range, 17e148) of the opposite side at enrollment to a
mean of 88  27% (range, 42e217) at follow-up (P ¼ 0.010). Pinchstrength improved slightly, but signiﬁcantly from a mean of
84  21% (range, 26e161) at enrollment to a mean of 91  19%
(range, 41e133) at follow-up (P ¼ 0.015).
Operative treatment
Only 10 of 113 patients (9%) e including seven that completed
the protocol and three that did note elected operative treatment to
date (at an average follow-up of 3.9 years) at one of the nine major
regional hospitals that share our electronic medical record, eight in
the practice of the same surgeon that prescribed the study splint,
and two in the practice of another surgeon. Surgeon A operated on
ﬁve patients (22%), and surgeon B, who was less likely to operate
Table III





Cohort (neoprene vs thermoplast) NS 0.69
Sex 0.26 0.042
Dominant hand affected NS 0.60
KruskaleWallis test
Marital status NS 0.55
Affected thumb NS 0.69
Spearman correlation
Age (years) NS 0.85




Whiteley Index NS 0.069
Bivariable analysis with response variables
Spearman correlation
Pain 0.53 <0.0001
Grip strength (%) 0.39 0.0017
Pinch strength (%) 0.37 0.0032
The numbers in bold indicate signiﬁcant P values (P < 0.05).
Table V





Cohort (Neoprene vs Thermoplast) NS 0.78
Sex NS 0.16
Dominant hand affected NS 0.52
KruskaleWallis Test
Marital status NS 0.94
Affected thumb NS 0.67
Spearman correlation
Baseline
Age (years) NS 0.42




Whiteley Index NS 0.32
Follow-up
Follow-up time (weeks) NS 0.67




Grip strength (%) NS 0.67
Pinch strength (%) NS 0.64
Follow-up
DASH 0.46 0.00014
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somewhere else, operated on three patients (3.3%).Improvement of DASH score NS 0.16
Grip strength (%) 0.25 0.046
Pinch strength (%) NS 0.094
The numbers in bold indicate signiﬁcant P values (P < 0.05).Discussion
Our primary null hypothesis that there would be no difference
between arm-speciﬁc disability at follow-up was not rejected in
this sample. The neoprene splint was on averagemore comfortable,
but otherwise comparable to the thermoplast splint in our sample.Table IV





Cohort (Neoprene vs Thermoplast) NS 0.71
Sex NS 0.21
Dominant hand affected NS 0.85
KruskaleWallis Test
Marital status NS 0.30
Affected thumb NS 0.38
Spearman Correlation
Baseline
Age (years) NS 0.23




Whiteley Index 0.33 0.0098
Follow-up
Follow-up time (weeks) NS 0.17




Grip strength (%) 0.34 0.0069
Pinch strength (%) NS 0.26
Follow-up
Pain 0.46 0.00014
Improvement of pain NS 0.71
Grip strength (%) NS 0.057
Pinch strength (%) 0.44 0.00036
The numbers in bold indicate signiﬁcant P values (P < 0.05).This was a superiority trial, so we cannot conclude that the splints
are equivalent, only that this trial did not show evidence of a
clinically meaningful advantage for one splint over the other.
Average pain, grip and pinch strength all improved signiﬁcantly
with either splint, but the average arm-speciﬁc disability (DASH)
did not change. Most patients either did not return or continued
nonoperative treatment, so at a minimum, splints provide patients
time to reﬂect on their disease and adjust to it.
The strengths of this study were that the design was a pro-
spective randomized trial with adequate power for detecting a
clinically relevant difference in DASH score; that the splints were
only different in terms ofmaterial; and that a research assistant, not
involved in patient care, took the measurements.
This study was designed and powered for a single primary study
question addressing disability 5e15 weeks after splint prescription.
With the caveat that we were only interested in substantial
differences in DASH score, we were not able to reject our null
hypothesis, but the conﬁdence interval was wide (95% CI, 7.4 to
7.7), so it is possible that differences smaller than 10 points on the
DASH might be detected in a larger trial. All of the secondary study
questionse including the difference in patient preferences e should
be considered hypothesis-generating. Additional limitations of this
study were the use of DASH scores with up to ﬁve missing answers
instead of the validated three missing items; the reliance on clinical
rather than a radiological diagnosis of TMC arthrosis which did not
account for the degree of objective pathophysiology; the length of
follow-up which might be speciﬁc to our practice; the research as-
sistantwho evaluated patients at both time pointswas not blinded to
the randomization; the use of follow-up data from three patients
who completed the protocol later than the accepted time-frame; and
the large number of patients that did not complete the study. Satis-
ﬁed patients may not have felt the need to return, which could
explain the high loss to follow-up (43%) and the relatively low
recorded satisfaction; however, the opposite may also be true. This
Table VI
Bivariable analysis - satisfaction scores. The numbers in bold indicate signiﬁcant P values (P < 0.05)
n ¼ 62

















NS 0.19 NS 0.43 NS 0.51 NS 0.45 0.25 0.048 NS 0.13
Sex NS 0.34 NS 0.12 0.26 0.037 NS 0.053 NS 0.50 NS 0.60
Dominant hand affected NS 0.44 NS 0.86 NS 0.90 NS 0.87 NS 0.74 NS 0.59
KruskaleWallis Test
Marital status NS 0.32 NS 0.12 NS 0.18 NS 0.18 NS 0.25 NS 0.19
Affected thumb NS 0.42 NS 0.75 NS 0.89 NS 0.96 NS 0.95 NS 0.22
Spearman correlation
Baseline
Age (years) NS 0.25 NS 0.28 NS 0.11 NS 0.31 NS 0.52 NS 0.32
Education (years) NS 0.99 NS 0.63 NS 0.91 NS 0.76 NS 0.47 NS 0.78
PASS NS 0.25 NS 0.46 NS 0.73 NS 0.85 NS 0.49 NS 0.094
PCS NS 0.70 NS 0.52 NS 0.91 NS 0.71 NS 0.53 0.29 0.022
CES-D NS 0.28 NS 0.28 NS 0.74 NS 0.67 NS 0.77 0.27 0.035
Whiteley Index NS 0.066 NS 0.42 NS 0.56 NS 0.67 NS 0.37 0.33 0.0099
Follow-up
Follow-up time (weeks) NS 0.78 NS 0.66 NS 0.49 NS 0.47 NS 0.73 NS 0.55
Bivariable analysis with response variables
Spearman Correlation
Baseline
DASH NS 0.40 NS 0.26 NS 0.15 NS 0.080 NS 0.27 NS 0.24
Pain NS 0.10 NS 0.13 NS 0.10 0.27 0.031 NS 0.053 NS 0.66
Grip strength (%) NS 0.90 NS 0.33 NS 0.22 NS 0.31 NS 0.51 NS 0.64
Pinch strength (%) NS 0.78 NS 0.37 NS 0.58 NS 0.61 NS 0.59 NS 0.64
Follow-up
DASH 0.28 0.029 NS 0.25 NS 0.39 NS 0.55 0.30 0.017 0.31 0.015
Improvement of DASH score 0.37 0.0034 0.27 0.032 0.30 0.016 0.34 0.0064 0.47 0.00012 NS 0.21
Pain NS 0.60 NS 0.91 NS 0.62 NS 0.78 NS 0.28 NS 0.69
Improvement of pain NS 0.11 NS 0.14 NS 0.39 NS 0.11 0.31 0.014 NS 0.86
Grip strength (%) NS 0.69 NS 0.63 NS 0.26 NS 0.66 NS 0.69 NS 0.34
Pinch strength (%) NS 0.064 NS 0.32 NS 0.71 NS 0.45 0.31 0.015 NS 0.19
The numbers in bold indicate signiﬁcant P values (P < 0.05).
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generalizability of this study, although the majority of our patients
come directly from primary care doctors in our network and did not
receive any previous treatment. The results should be interpreted in
light of the fact that these represent the average patient.
Partially consistent with our results, a review in 2007 concluded
that there was no superior splint in terms of comfort, pain relief or
function14. In 2004 and2011, two crossover trials compared a custom-
madethumbspica thermoplastic splintwith theMP joint free toapre-
fabricated shortneoprene splintwith theMP included, and found that
patients preferred the neoprene over the thermoplast splint4,5.
Splints signiﬁcantly, but modestly, decrease pain for TMC
arthrosis in this and prior studies3,4,15. Weiss et al.4 found that the
neoprene splint provided greater pain relief than the thermoplast
splint, while Sillem et al.5 found the opposite. In 2011, no between-
group difference in the effect on subjective and objective hand
functionwas found by Sillem et al.; although only the thermoplastic
splint signiﬁcantly improved subjective hand function5.
Disability with TMC arthrosis after splinting related more to
depression and heightened illness concern than demographics or
treatment details, but most of the variation in disability remains
unexplained. That depressive symptoms correlated with disability
is consistent with earlier research16,17.
Berggren et al.18 studied 33 patients seeking TMC arthroplasty
thatwere sent to an occupational therapist and randomized to one of
three treatment strategies: one group treated with adaptive acces-
sories (e.g., pen handle, book support, and bread saw) and the other
two groups treated with one of two splint types in addition totreatmentwith theaccessories.Duringa sevenmonth follow-uponly
30% had surgery, and after 7 years, during which time four patients
died, only two more patients requested operative treatment.
Based on the current study, and in the context of other data, we
would advise patients as follows: (1) a pre-fabricated, soft splint
providesmore comfortwith less cost thana custom-madeﬁrmsplint;
(2) the substantial variation in symptoms and disability remains
incompletely explained, but optimal mood and effective adaptive
strategies are important opportunities for less pain and better func-
tion; and (3) a small percentage of patients that seek attention for
TMC arthrosis request operative treatment within the ﬁrst 4 years or
so of their ﬁrst visit with a hand surgeon and after splint treatment.
The ﬁnding of minimal difference between splints on average
(neoprene slightly more comfortable and otherwise no differences)
suggests that surgeons and therapists can spend less time discussing
the technicalaspectsofvarioussplintoptionsandmore timecoaching
patients on other adaptive and palliative measures to help patients
manage their symptoms and remain as functional as possible.
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